Simple Summary Taking into consideration the high risk of patients with cancer for severe
COVID-19 infection, prioritization has been given to primary prevention with both primary …

Abstract Consensus Panel 5 (CP5) of the 11th International Workshop on Waldenstrom's
Macroglobulinemia (IWWM-11; held in October 2022) was tasked with reviewing the current …

Simple Summary Upon BNT162b2 mRNA vaccinations, multiple myeloma (MM) and
Waldenstrom's macroglobulinemia (WM) patient cohorts on active therapy affecting B cell …

Immune responses to primary COVID‐19 vaccination were investigated in 58 patients with
follicular lymphoma (FL) as part of the PETReA trial of frontline therapy (EudraCT 2016 …

Patients with hematologic diseases receiving anti-CD20 monoclonal antibodies show a low
seroconversion rate after two doses of mRNA Coronavirus disease-2019 (COVID-19) …

Patients with Waldenström macroglobulinaemia (WM) are at increased risk of severe COVID‐
19 infection and have poor immune responses to COVID‐19 vaccination. This study …

In order to elucidate mechanisms for severe acute respiratory syndrome coronavirus 2
vaccination success in hematological neoplasia, we, herein, provide a comprehensive …

Although a more efficient adaptive humoral immune response has been proposed to
underlie the usually favorable outcome of pediatric COVID-19, the breadth of viral and …

The worldwide rollout of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)
vaccinations in the last 2 years has produced a multitude of studies investigating T‐cell …

Despite widespread vaccination rates, we are living with high transmission rates of SARS‐
CoV‐2. Although overall hospitalisation rates are falling, the risk of serious infection remains …